Voyager Therapeutics (VYGR) –
-
Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting
-
Voyager Therapeutics (VYGR) Picks Development Candidate for GBA1 Program
-
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
-
NorthStar Appoints Peter Pfreundschuh to Board of Managers
-
Form 4 Voyager Therapeutics, For: Apr 01 Filed by: Ferguson Toby
-
Form 4 Voyager Therapeutics, For: Apr 02 Filed by: Swartz Robin
-
Form 4 Voyager Therapeutics, For: Apr 02 Filed by: Sandrock Alfred
-
Form 8-K Voyager Therapeutics, For: Mar 27
-
Form 144 Voyager Therapeutics, Filed by: Swartz Robin
-
Form 144 Voyager Therapeutics, Filed by: Sandrock Alfred
-
Form 4 Voyager Therapeutics, For: Mar 25 Filed by: Ferguson Toby
-
Form 3 Voyager Therapeutics, For: Mar 25 Filed by: Ferguson Toby
-
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Guggenheim Starts Voyager Therapeutics (VYGR) at Buy
-
H.C. Wainwright Starts Voyager Therapeutics (VYGR) at Buy, 'TRACER Capsids Lead the Way in Neurogenetic Medicines'
-
Form 8-K Voyager Therapeutics, For: Feb 29
-
Voyager Therapeutics (VYGR) Appoints Toby Ferguson as Chief Medical Officer
-
Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer
-
Citi Starts Voyager Therapeutics (VYGR) at Buy, 'premier player'
-
Form S-8 Voyager Therapeutics,
-
Form 10-K Voyager Therapeutics, For: Dec 31
-
Voyager Therapeutics (VYGR) Tops Q4 EPS by 154c
-
Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
-
Form 8-K Voyager Therapeutics, For: Feb 28
-
Voyager Therapeutics (VYGR) Announces Selection of Gene Therapy Development Candidate for Friedreich’s Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
-
Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
-
Form 4 Voyager Therapeutics, For: Feb 21 Filed by: Swartz Robin
-
Form 4 Voyager Therapeutics, For: Feb 21 Filed by: Sandrock Alfred
-
Form 4 Voyager Therapeutics, For: Feb 21 Filed by: PFREUNDSCHUH PETER P.
-
Form 4 Voyager Therapeutics, For: Feb 20 Filed by: Carter Todd Alfred
-
Form 144 Voyager Therapeutics, Filed by: Sandrock Alfred
-
Form 144 Voyager Therapeutics, Filed by: PFREUNDSCHUH PETER P.
-
Form 144 Voyager Therapeutics, Filed by: Swartz Robin
-
Form 144 Voyager Therapeutics, Filed by: Carter Todd Alfred
-
Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and Webcast
-
Form 144 Voyager Therapeutics, Filed by: Carter Todd Alfred
-
Voyager Therapeutics (VYGR) Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer’s Disease and Advances Program into Late Research
-
Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer’s Disease and Advances Program into Late Research
-
Form 4 Voyager Therapeutics, For: Feb 09 Filed by: Fahey Sandell Jacquelyn
-
Form 4 Voyager Therapeutics, For: Feb 09 Filed by: Carter Todd Alfred
-
Form 4 Voyager Therapeutics, For: Feb 09 Filed by: Swartz Robin
-
Form 4 Voyager Therapeutics, For: Feb 09 Filed by: Sandrock Alfred
-
Form 4 Voyager Therapeutics, For: Feb 09 Filed by: PFREUNDSCHUH PETER P.
-
Form SC 13G/A Voyager Therapeutics, Filed by: Third Rock Ventures III, L.P.
-
Form SC 13G/A Voyager Therapeutics, Filed by: ARMISTICE CAPITAL, LLC
-
Form SC 13G/A Voyager Therapeutics, Filed by: VANGUARD GROUP INC
-
Voyager Therapeutics to Present at the Oppenheimer Annual Life Sciences Conference
-
Form SC 13G Voyager Therapeutics, Filed by: BlackRock Inc.
-
Form 4 Voyager Therapeutics, For: Jan 17 Filed by: Swartz Robin
-
Form 4 Voyager Therapeutics, For: Jan 17 Filed by: Carter Todd Alfred
Back to VYGR Stock Lookup
